Dose-ranging study of CP-99,219 (trovafloxacin) for treatment of uncomplicated gonorrhea.
AUTOR(ES)
Hook, E W
RESUMO
Thirty-nine patients with uncomplicated gonorrhea were randomized to receive single, oral 50-, 100-, or 200-mg doses of trovafloxacin (CP-99,219), a new quinolone antibiotic. All 31 evaluable patients were cured of infection. Trovafloxacin was well tolerated. The trovafloxacin MICs at which 50 and 90% of 36 Neisseria gonorrhoeae isolates are inhibited were 0.002 and 0.004 mg/liter, respectively (MIC range, < 0.0005 to 0.008 mg/liter). These preliminary studies suggest that trovafloxacin is effective for the treatment of uncomplicated gonorrhea at single oral doses as low as 50 mg.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=163403Documentos Relacionados
- Dose-Ranging Study of Ceftriaxone for Uncomplicated Gonorrhea in Men
- Dose-Ranging Study of Ceftriaxone for Uncomplicated Gonorrhea in Men
- Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections.
- Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
- Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.